Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes

This multicenter randomized trial evaluated the efficacy of intermittently scanned continuous glucose monitoring (isCGM; FreeStyle Libre 2 with optional alarms) versus fingerstick blood glucose monitoring in 156 adults with type 1 diabetes and elevated HbA1c (7.5–11.0%). At 24 weeks, the isCGM group showed:

• HbA1c reduction: Adjusted mean difference of 0.5% (95% CI: 0.7 to 0.3; P<0.001) compared to usual care.

• Time in range: 9.0 percentage points (130 minutes/day) longer in target range (70–180 mg/dL).

• Hypoglycemia reduction: 3.0 percentage points (43 minutes/day) less time <70 mg/dL.

• Safety: Few adverse events (1 skin reaction in isCGM group vs. 2 severe hypoglycemia episodes in control group).
  The study demonstrates that isCGM significantly improves glycemic control and reduces hypoglycemia in poorly controlled type 1 diabetes.

This multicenter randomized trial evaluated the efficacy of intermittently scanned continuous glucose monitoring (isCGM; FreeStyle Libre 2 with optional alarms) versus fingerstick blood glucose monitoring in 156 adults with type 1 diabetes and elevated HbA1c (7.5–11.0%). At 24 weeks, the isCGM group showed:

• HbA1c reduction: Adjusted mean difference of 0.5% (95% CI: 0.7 to 0.3; P<0.001) compared to usual care.

• Time in range: 9.0 percentage points (130 minutes/day) longer in target range (70–180 mg/dL).

• Hypoglycemia reduction: 3.0 percentage points (43 minutes/day) less time <70 mg/dL.

• Safety: Few adverse events (1 skin reaction in isCGM group vs. 2 severe hypoglycemia episodes in control group).
  The study demonstrates that isCGM significantly improves glycemic control and reduces hypoglycemia in poorly controlled type 1 diabetes.